Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Germany's Merck Returns Safinamide To Newron, Merger With Biotie Now Under Review

This article was originally published in The Pink Sheet Daily

Executive Summary

The surprise announcement by Merck Serono to return all rights to safinamide to Italy's Newron has led to Biotie Therapies and Newron reviewing their plans to merge.

You may also be interested in...



CHMP Positive On Safinamide, First New Parkinson’s Therapy In 10 Years

Newron expects partner Zambon to start marketing safinamide in the first half of 2015 in Europe, and to resubmit it soon for U.S. approval. Other positive CHMP opinions this month include Orexigen’s obesity therapy Mysimba and Durata’s antibiotic Xydalba.

Deals Of The Week: Upsher-Smith/Proximagen, Novo Nordisk/JDRF, Newron/NeuroNova

With BIO 2012 taking place June 17-21, the entire health care world awaits the Supreme Court’s ruling on health care reform. In the pharma world, companies are strategizing against all the possible outcomes.

Newron Overcomes 2011 Disappointments, Moves To Boost CNS Pipeline With NeuroNova Acquisition

Italy's Newron aims to become a leading European CNS-focused biotech company with the proposed acquisition of Sweden's NeuroNova adding product candidates in ALS and Parkinson's disease to its portfolio.

Related Content

Topics

UsernamePublicRestriction

Register

OM013057

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel